Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical implications of isolated troponinemia following immune checkpoint inhibitor therapy
Danielle Delombaerde, Delphine Vervloet, Constantijn Franssen, et al.
ESMO Open (2021) Vol. 6, Iss. 4, pp. 100216-100216
Open Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
Alexander R. Lyon, Teresa López‐Fernández, Liam S. Couch, et al.
European Heart Journal (2022) Vol. 43, Iss. 41, pp. 4229-4361
Open Access | Times Cited: 1579
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
Alexander R. Lyon, Teresa López‐Fernández, Liam S. Couch, et al.
European Heart Journal - Cardiovascular Imaging (2022) Vol. 23, Iss. 10, pp. e333-e465
Open Access | Times Cited: 211
Cardiovascular toxicity of immune therapies for cancer
Nicolas L. Palaskas, Hyeon-Ju Ali, Efstratios Koutroumpakis, et al.
BMJ (2024), pp. e075859-e075859
Closed Access | Times Cited: 10
Recent Advances in Serum Biomarkers for Risk Stratification and Patient Management in Cardio-Oncology
Pouya Joolharzadeh, Mario Rodriguez, Raja Zaghlol, et al.
Current Cardiology Reports (2023) Vol. 25, Iss. 3, pp. 133-146
Open Access | Times Cited: 17
Uncovering the flip side of immune checkpoint inhibitors: a comprehensive review of immune-related adverse events and predictive biomarkers
Yandong Miao, Wuxia Quan, Xiaolong Tang, et al.
International Journal of Biological Sciences (2024) Vol. 20, Iss. 2, pp. 621-642
Open Access | Times Cited: 7
Complementary use of cardiac magnetic resonance and 18 F-FDG positron emission tomography imaging in suspected immune checkpoint inhibitor myocarditis
Jieli Tong, N. Vogiatzakis, María Sol Andrés, et al.
Cardio-Oncology (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 6
Role of Cardiac Biomarkers in Cancer Patients
Gennaro Carmine Semeraro, Carlo M. Cipolla, Daniela Cardinale
Cancers (2021) Vol. 13, Iss. 21, pp. 5426-5426
Open Access | Times Cited: 33
Preclinical models of cardiotoxicity from immune checkpoint inhibitor therapy
Florian Buehning, Tobias Lerchner, Julia K. Vogel, et al.
Basic Research in Cardiology (2024)
Open Access | Times Cited: 5
Pathophysiology of Immune Checkpoint Inhibitor-Induced Myocarditis
Rosa Jiménez-Alejandre, Ignacio Ruiz‐Fernández, Pilar Martı́n
Cancers (2022) Vol. 14, Iss. 18, pp. 4494-4494
Open Access | Times Cited: 22
Real life management of elevated troponin in patients treated with immune checkpoint inhibitors
Lior Zornitzki, Dana Viskin, Ophir Freund, et al.
CJC Open (2025)
Open Access
Effects of Immune Checkpoint Inhibitor-induced Thyroid Dysfunction on Cardiac Troponin Levels
Yuma Shibutani, Atsushi Kawanobe, Shinya Suzuki, et al.
Journal of Immunotherapy (2025)
Closed Access
The role of prehabilitation in HNSCC patients treated with chemoradiotherapy
Riccardo Gili, Sacco Gianluca, Archetti Paolo, et al.
Supportive Care in Cancer (2024) Vol. 32, Iss. 10
Open Access | Times Cited: 3
Breast cancer and cardiovascular health
Teresa López‐Fernández, Irene Marco Clement, M.C. Aznar, et al.
European Heart Journal (2024) Vol. 45, Iss. 41, pp. 4366-4382
Closed Access | Times Cited: 3
Immune-Checkpoint Inhibitor-Related Myocarditis: Where We Are and Where We Will Go
Andrea Vergara, Marco De Felice, Arturo Cesaro, et al.
Angiology (2023) Vol. 75, Iss. 10, pp. 909-920
Closed Access | Times Cited: 9
A case of subclinical immune checkpoint inhibitor-associated myocarditis in non-small cell lung cancer
Yue Hu, Cuixia Liu, Shaojun Jin, et al.
BMC Pulmonary Medicine (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 8
Cardiac Biomarkers for the Detection and Management of Cancer Therapy-Related Cardiovascular Toxicity
Xinxin Zhang, Yuxi Sun, Yanli Zhang, et al.
Journal of Cardiovascular Development and Disease (2022) Vol. 9, Iss. 11, pp. 372-372
Open Access | Times Cited: 13
Management of respiratory failure in immune checkpoint inhibitors-induced overlap syndrome: a case series and review of the literature
John Cuenca, Ankit Hanmandlu, Robert Wegner, et al.
BMC Anesthesiology (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 7
Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies
Jutta Bergler‐Klein, Peter P. Rainer, Markus Wallner, et al.
Wiener klinische Wochenschrift (2022) Vol. 134, Iss. 17-18, pp. 654-674
Open Access | Times Cited: 12
Immune checkpoint inhibitor-associated cardiovascular toxicities: A review
Guihong Liu, Tao Chen, Xin Zhang, et al.
Heliyon (2024) Vol. 10, Iss. 5, pp. e25747-e25747
Open Access | Times Cited: 2
Cardiotoxicity induced by immune checkpoint inhibitor: The complete insight into mechanisms, monitoring, diagnosis, and treatment
Sridha Ganesh, Peng Zhong, Xiaoyang Zhou
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 10
Extensive CArdioVAscular Characterization and Follow-Up of Patients Receiving Immune Checkpoint Inhibitors: A Prospective Multicenter Study
Danielle Delombaerde, Johan De Sutter, Lieselot Croes, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 4, pp. 625-625
Open Access | Times Cited: 4
Aberrant Expression of Cardiac Troponin-T in Lung Cancer Tissues in Association With Pathological Severity
Toshihiro Tsuruda, Yuichiro Sato, Masaki Tomita, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 5
Immune Checkpoint Inhibitor-Induced Myocarditis vs. COVID-19 Vaccine-Induced Myocarditis—Same or Different?
Lior Zornitzki, Ofer Havakuk, Zach Rozenbaum, et al.
Life (2022) Vol. 12, Iss. 9, pp. 1366-1366
Open Access | Times Cited: 5
Quantitation of cardiac troponin I in cancer patients treated with immune checkpoint inhibitors: a case-control study
Antigona Ulndreaj, Davor Brinc, Mehmet Altan, et al.
Clinical Chemistry and Laboratory Medicine (CCLM) (2022) Vol. 61, Iss. 1, pp. 154-161
Closed Access | Times Cited: 3
Close Cardiovascular Monitoring during the Early Stages of Treatment for Patients Receiving Immune Checkpoint Inhibitors
Danielle Delombaerde, Christof Vulsteke, Nico Van de Veire, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 7, pp. 965-965
Open Access
Page 1 - Next Page

Scroll to top